Close Menu

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Tuesday that its first quarter revenues fell nearly 6 percent year over year as its net loss increased 43 percent.

For the three months ended March 31, the liquid biopsy MDx developer reported revenues of $120,000 compared to $127,000 in Q1 2015, falling short of analysts' estimate of $260,000.

Trovagene reported $113,000 in royalty revenues compared to $125,000 in Q1 2015, and $7,000 in diagnostic service revenues, up from $2,000 in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.